CA2998523C - Detecting and treating growth hormone deficiency - Google Patents

Detecting and treating growth hormone deficiency Download PDF

Info

Publication number
CA2998523C
CA2998523C CA2998523A CA2998523A CA2998523C CA 2998523 C CA2998523 C CA 2998523C CA 2998523 A CA2998523 A CA 2998523A CA 2998523 A CA2998523 A CA 2998523A CA 2998523 C CA2998523 C CA 2998523C
Authority
CA
Canada
Prior art keywords
test
growth
response
testing
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2998523A
Other languages
English (en)
French (fr)
Other versions
CA2998523A1 (en
Inventor
Michael THORNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of CA2998523A1 publication Critical patent/CA2998523A1/en
Application granted granted Critical
Publication of CA2998523C publication Critical patent/CA2998523C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2998523A 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency Active CA2998523C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US62/221,191 2015-09-21
US201662289221P 2016-01-30 2016-01-30
US62/289,221 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Publications (2)

Publication Number Publication Date
CA2998523A1 CA2998523A1 (en) 2017-03-30
CA2998523C true CA2998523C (en) 2023-08-01

Family

ID=58276481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998523A Active CA2998523C (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Country Status (23)

Country Link
US (4) US9763919B2 (enExample)
EP (3) EP3352752B1 (enExample)
JP (5) JP6816149B2 (enExample)
KR (4) KR20250102122A (enExample)
CN (2) CN116459250A (enExample)
AU (5) AU2016328969B2 (enExample)
CA (1) CA2998523C (enExample)
CY (1) CY1125183T1 (enExample)
DK (2) DK3352752T3 (enExample)
ES (2) ES2967259T3 (enExample)
FI (1) FI3939590T3 (enExample)
HR (1) HRP20220317T1 (enExample)
HU (2) HUE057831T2 (enExample)
IL (1) IL258224B (enExample)
LT (1) LT3352752T (enExample)
PL (2) PL3939590T3 (enExample)
PT (2) PT3352752T (enExample)
RS (1) RS62988B1 (enExample)
SG (2) SG10202010598SA (enExample)
SI (1) SI3352752T1 (enExample)
SM (1) SMT202200167T1 (enExample)
UA (1) UA123865C2 (enExample)
WO (1) WO2017053373A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220142989A1 (en) * 2015-09-21 2022-05-12 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
AU2016328969B2 (en) * 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102880573B1 (ko) 2018-08-20 2025-11-04 베서, 파마 엘엘씨 칸나비노이드의 생성 공정
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650597A4 (en) 1992-06-29 1996-12-18 Univ South Florida DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH.
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ES2275313T3 (es) 1997-08-22 2007-06-01 Kaken Pharmaceutical Co., Ltd. Derivados de amida como promotores de la liberacion de la hormona del crecimiento.
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
AR029941A1 (es) 2000-06-13 2003-07-23 Zentaris Gmbh Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
WO2005027894A1 (en) * 2003-09-19 2005-03-31 Pfizer Health Ab Enhanced method of treatment of growth disorders
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
AU2016328969B2 (en) * 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency

Also Published As

Publication number Publication date
IL258224B (en) 2021-10-31
US20190015394A1 (en) 2019-01-17
AU2025237934A1 (en) 2025-10-16
KR20220047407A (ko) 2022-04-15
PT3939590T (pt) 2024-01-23
AU2024201658B2 (en) 2025-10-30
AU2020233715A1 (en) 2020-10-22
US9763919B2 (en) 2017-09-19
HUE057831T2 (hu) 2022-06-28
CN108348501A (zh) 2018-07-31
AU2021254600A1 (en) 2021-11-18
KR102560838B1 (ko) 2023-07-27
US20250213536A1 (en) 2025-07-03
SG10201902424TA (en) 2019-04-29
JP2024026112A (ja) 2024-02-28
CY1125183T1 (el) 2023-06-09
AU2016328969A1 (en) 2018-04-26
FI3939590T3 (fi) 2023-12-14
AU2020233715B2 (en) 2021-09-30
JP7104768B2 (ja) 2022-07-21
AU2016328969B2 (en) 2020-10-08
DK3939590T3 (da) 2023-12-18
US10105352B2 (en) 2018-10-23
KR20180082428A (ko) 2018-07-18
US20170079961A1 (en) 2017-03-23
KR20230116961A (ko) 2023-08-04
HUE065224T2 (hu) 2024-05-28
US10898472B2 (en) 2021-01-26
AU2024201658A1 (en) 2024-04-04
EP4296679A3 (en) 2024-04-10
ES2908423T3 (es) 2022-04-29
EP3352752A1 (en) 2018-08-01
SI3352752T1 (sl) 2022-05-31
SMT202200167T1 (it) 2022-05-12
KR102385669B1 (ko) 2022-04-13
EP3939590B1 (en) 2023-11-29
UA123865C2 (uk) 2021-06-16
ES2967259T3 (es) 2024-04-29
SG10202010598SA (en) 2020-11-27
PL3352752T3 (pl) 2022-04-19
JP7724831B2 (ja) 2025-08-18
JP7389862B2 (ja) 2023-11-30
KR20250102122A (ko) 2025-07-04
CN116459250A (zh) 2023-07-21
EP3352752B1 (en) 2021-12-22
US20180071266A1 (en) 2018-03-15
JP6816149B2 (ja) 2021-01-20
IL258224A (en) 2018-05-31
LT3352752T (lt) 2022-04-11
JP2022163012A (ja) 2022-10-25
JP2021063096A (ja) 2021-04-22
JP2018529766A (ja) 2018-10-11
EP3352752A4 (en) 2019-06-12
EP4296679A2 (en) 2023-12-27
JP2025170274A (ja) 2025-11-18
PL3939590T3 (pl) 2024-03-25
RS62988B1 (sr) 2022-03-31
HRP20220317T1 (hr) 2022-05-13
WO2017053373A1 (en) 2017-03-30
PT3352752T (pt) 2022-03-09
HK1263178A1 (zh) 2020-01-31
AU2021254600B2 (en) 2024-02-15
CA2998523A1 (en) 2017-03-30
NZ741142A (en) 2025-05-02
DK3352752T3 (da) 2022-02-28
EP3939590A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
AU2021254600B2 (en) Detecting and treating growth hormone deficiency
US11234969B2 (en) Detecting and treating growth hormone deficiency
US20220142989A1 (en) Detecting and treating growth hormone deficiency
HK40068057B (en) Detecting and treating growth hormone deficiency
HK40105706A (en) Detecting and treating growth hormone deficiency
HK40068057A (en) Detecting and treating growth hormone deficiency
HK1263178B (en) Detecting and treating growth hormone deficiency

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730

EEER Examination request

Effective date: 20210730